Business
NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI
TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced the appointment of Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath, as Fractional Chief Medical Officer, marking an important step in the Company’s evolution as it advances toward broader globa
About this update from Netramark Holdings Inc
[{"type":"image","alt":"NetraMark Holdings Inc.","displaySize":"","headline":null,"caption":"NetraMark Holdings Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/192769f9f65e10ea97c7137b2337b7be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cKmM3wfaRebYT3SszZY1sQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/192769f9f65e10ea97c7137b2337b7be","width":300,"height":94}},"lazy":false},{"type":"text","content":"TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced the appointment of Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath, as Fractional Chief Medical Officer, marking an important step in the Company’s evolution as it advances toward broader global deployment of its NetraAI platform.","length":537,"tagName":"p"},{"type":"text","content":"Dr. Theocharous currently serves and will continue to serve as Chief Therapeutics & Clinical Strategy Officer (CTCSO) and President of Europe at Worldwide Clinical Trials, bringing NetraMark deep expertise across clinical development, therapeutic strategy, and global trial execution. His appointment reinforces NetraMark’s commitment to integrating world-class clinical leadership into its AI-driven approach to transforming clinical trials.","length":446,"tagName":"p"},{"type":"text","content":"In his role, Dr. Theocharous will work closely with NetraMark’s executive team to guide clinical strategy and the translation of NetraAI insights into actionable decisions across trial design, patient stratification and enrichment.","length":231,"tagName":"p"},{"type":"text","content":"“This is an important appointment for NetraMark. Dr. Theocharous operates at a high level of clinical strategy within the global drug development ecosystems. His decision to join us reflects both the strength of our technology and the growing recognition that the future of clinical trials will be driven by explainable AI,” said George Achilleos, CEO of NetraMark. “As we deepen our collaboration across the industry, we believe his perspective will be instru...